

REMARKS

Claims 120, 122, 124, 127-130, and 141-171 are presently pending in the application.

Claims 120, 122, 124 and 127 and 144-147 are independent claims.

Claims 121 and 123 have been canceled and the subject matter thereof incorporated into claims 120 and 122, respectively. Claim 127 has also been amended to add structure I. Claims 120, 122, 124 and 127 have been amended to recite a pharmaceutical composition which comprises a pharmaceutically acceptable carrier, in addition to the calixpyrrole macrocycle.

Support for this amendment may be found in the specification at least in paragraph [0216] (using the paragraph numbering in the published application, which corresponds to the application as filed, for convenience). Claims 120, 122 and 124 have been amended to recite that the macrocycle is complexed to a halide anion, which is supported at least in paragraph [0100]. Claims 128-130 have been amended to correctly depend from amended claim 127. No new matter has been added by these amendments.

New claims 141-143 are identical to claim 130 but depend from claims 120, 122, and 124, respectively. New claims 144-151 are similar to claims 120, 122, 124, 127, 130 and 141-143, but recite a composition in which the macrocycle is attached to a solid support, which is supported in the specification at least in paragraphs [0024] and [0049]. Finally, new claims 152-171 recite specific solid supports and forms of solid supports, which are supported at least in paragraphs [0190] and [0365]. No new matter has been added by these amendments, and entry is respectfully requested. It is submitted that these amendments are proper after final since they are mainly formal in nature and/or were suggested by the Examiner, and will place the application in condition for allowance, as explained below.

In the present Office Action, the Examiner has again rejected claims 120-124 and 127-130 under 35 U.S.C. § 112, first paragraph, as lacking enablement, maintaining that the claims are only enabled for pharmaceutical compositions and compositions of the macrocycle attached to solid supports. The Examiner states that the rejection can be overcome by amending the claims to recite "pharmaceutical compositions" and including a pharmaceutically acceptable carrier, or by including specific solid supports attached to the calix[n]pyrroles.

The Examiner has also maintained the objection to claims 120-124 and 127-130, arguing that the claims still contain non-elected subject matter, not being drawn to structure I and being non-covalently complexed to other than a halide anion.

While not agreeing with the Examiner's objections or rejections, in order to advance prosecution of this application, Applicants have amended claims 120, 122, 124 and 127 as suggested by the Examiner to delete the non-elected subject matter. Further, the pending claims between 120 and 143 now recite pharmaceutical compositions which additionally comprise a pharmaceutically acceptable carrier, as suggested by the Examiner. Finally, claims 144-151 recite similar compositions in which the macrocycle is attached to a solid support, which were also suggested by the Examiner. Accordingly, it is respectfully submitted that the pending claims are in full compliance with § 112, first paragraph. Additionally, it is respectfully requested that these claims be entered after final since the Examiner has already searched the subject matter recited therein (and has previously acknowledged that the subject matter is patentable over the prior art) and these amendments will place the application in condition for allowance.

Application No. 09/838,998

Response to Office Action of August 22, 2005

In view of the preceding Amendments and Remarks, it is respectfully submitted that all of the pending claims are in compliance with § 112, patentable, distinct from the prior art of record, and in condition for allowance. A Notice of Allowance is respectfully requested.

Respectfully submitted,

PHILIP A. GALE *et al.*

November 17, 2005
(Date)

By:


SANDRA M. KATZ

Registration No. 51,864

AKIN GUMP STRAUSS HAUER & FELD LLP

One Commerce Square

2005 Market Street, Suite 2200

Philadelphia, PA 19103-7013

Telephone: 215-965-1200

Direct Dial: 215-965-1344

Facsimile: 215-965-1210

E-Mail: skatz@akingump.com

ASN/SMK:smk